24 November 2024

Tag: cannabis

Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)

Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…

4 March 2021
Delic Holdings (DELC.C) acquires licensed psilocybin/cannabis lab, is doing legal shroom business

For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do business legally for years. To be fair, there’s some basis to that dismissal. But only some. We’ve also been talking about how Delic Holdings (DELC.C) was an all-star team of…

26 February 2021
Pure Extracts (PULL.C) submits 20 SKUs to Health Canada, based on its proprietary CO2 extraction technology

PULL submitted over 20 Stock Keeping Units (SKU) product identifiers for approval including THC vapes, CBD vapes, 1:1 blended vapes, and 3 different flavours/formulations of gummies.

25 February 2021
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date

“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.

25 February 2021
Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test

The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.

23 February 2021
Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies

Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie-manufacturing machines, certified to Canadian standards.

16 February 2021
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills

I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…

5 February 2021
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine

Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.

29 January 2021
Heritage Cannabis Holdings (CANN.C) closes the door on Premium 5 acquisition and refines growth strategy

Heritage Cannabis Holdings (CANN.C) closed its acquisition of Canadian-based recreational and medical cannabis company, Premium 5, today, according to a press release. Premium 5 products have stretched to retailers across eight provinces, and is one of the only concentrate brands available to medical patterns from coast to coast through both the Shoppers Drug Mart and…

27 January 2021
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale

If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…

22 January 2021